Cho Li-Wei, Sathyapalan Thozhukat, Kilpatrick Eric S, Keevil Brian G, Miller Adrian G, Coady Anne M, Ahmed Lina, Atkin Stephen L
Department of Endocrinology, Changi General Hospital, ᅟSingapore, Singapore.
Department of Academic Diabetes, Endocrinology and Metabolism, University of Hull, ᅟHull, UK.
BMC Endocr Disord. 2017 May 19;17(1):26. doi: 10.1186/s12902-017-0177-3.
Androsterone glucuronide (ADTG) concentrations have been suggested as a marker of the effects of androgens at the target tissue level. As the mechanism for hyperandrogenemia in obese and nonobese polycystic ovary syndrome (PCOS) may differ, this study compared the different androgen parameters in non-obese compared to obese women with PCOS, and in normal subjects.
Eleven non-obese and 14 obese women with PCOS were recruited and compared to 11 control women without PCOS. Total testosterone, dehydroepiandrosterone sulphate (DHEAS), ADTG, and androstenedione were analysed using gold standard tandem mass spectrometry, and the free androgen index (FAI) was calculated.
Total testosterone, ADTG and androstendione levels did not differ between non-obese (body mass index (BMI) ≤25 kg/m) and obese PCOS (BMI >25 kg/m) but all were significantly higher than for controls (p < 0.01). The ADTG to DHEAS ratio was significantly elevated 39 ± 6 (p < 0.01) in obese PCOS in comparison to non-obese PCOS and controls (28 ± 5 and 29 ± 4, respectively). The free androgen index (FAI) and insulin resistance (HOMA-IR) were significantly higher in obese PCOS compared to non-obese PCOS and controls (p < 0.01). DHEAS was significantly higher in the non-obese versus obese PCOS (p < 0.01). All androgen parameters were significantly lower and sex hormone binding globulin (SHBG) significantly higher in normal subjects compared to those with obese and non-obese PCOS.
The ADTG:DHEAS ratio was significantly elevated in obese PCOS compared to non-obese PCOS and controls suggesting that this may be a novel biomarker discriminatory for obese PCOS subjects, perhaps being driven by higher hepatic 5α reductase activity increasing ADTG formation in these women.
雄酮葡糖苷酸(ADTG)浓度被认为是雄激素在靶组织水平作用的一个标志物。由于肥胖和非肥胖多囊卵巢综合征(PCOS)患者高雄激素血症的机制可能不同,本研究比较了非肥胖与肥胖PCOS女性以及正常受试者之间不同的雄激素参数。
招募了11名非肥胖和14名肥胖PCOS女性,并与11名无PCOS的对照女性进行比较。使用金标准串联质谱法分析总睾酮、硫酸脱氢表雄酮(DHEAS)、ADTG和雄烯二酮,并计算游离雄激素指数(FAI)。
非肥胖(体重指数(BMI)≤25kg/m²)和肥胖PCOS(BMI>25kg/m²)女性的总睾酮、ADTG和雄烯二酮水平无差异,但均显著高于对照组(p<0.01)。与非肥胖PCOS和对照组(分别为28±5和29±4)相比,肥胖PCOS患者的ADTG与DHEAS比值显著升高至39±6(p<0.01)。肥胖PCOS患者的游离雄激素指数(FAI)和胰岛素抵抗(HOMA-IR)显著高于非肥胖PCOS和对照组(p<0.01)。非肥胖PCOS患者的DHEAS显著高于肥胖PCOS患者(p<0.01)。与肥胖和非肥胖PCOS患者相比,正常受试者的所有雄激素参数均显著较低,而性激素结合球蛋白(SHBG)显著较高。
与非肥胖PCOS和对照组相比,肥胖PCOS患者的ADTG:DHEAS比值显著升高,提示这可能是肥胖PCOS患者的一种新型生物标志物,可能是由这些女性肝脏5α还原酶活性升高导致ADTG生成增加所驱动。